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ABSTRACT 
In the present study, MDRP shows that ampicillin, cotrimoxazole, gentamycin, tetracycline, were resistant. Whereas ceftriaxon e with sulbactam, 
ciprofloxacin, ofloxacin was sensitive. The azithromycin and cefpodoxime were intermediate against S. typhi. The antibiotic susceptibility 
pattern of S. typhi during the period from Sep 2016 to June 2017and it was found that out of 676 the most sensitive antibiotics were ceftriaxone 
and sulbactam 90 (100%), ciprofloxacin 90 (100%) and ofloxacin 90 (100%) whereas the most resistant antibiotics were tetracycline 237 
(87.77%) and amoxycillin 225 (83.33%). The change in sensitivity pattern during the period of Sep 2016 to June 2017, July 2016 to 1 April 
2018 and May 2018 to Feb 2019 of the drug ceftriaxone and sulbactam, is 100%. The drug cefuroxime is 97.77%, 100 %, and 96.60%. The drug 
ciprofloxacin 100%, 100%, and 97.57%. The drug ofloxacin is 100%, 94.00%, and 92.23%. The drug amikacin 96.66%, 80.00%, and 50.48%. 
Out of 676 isolates of S. typhi, the MDR for two drug combination cotrimoxazole and nalidixic acid is 35 (5.17%).  
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INTRODUCTION 
The global estimates for the burden of invasive Salmonella 
disease found that South-Central and East-Central Asia 
experienced the highest incidences of typhoid fever, with 
>100 cases per 100000 person-years of observation1. The 
incidence rates of typhoid fever in many of the Typhoid 
Fever Surveillance in Africa Program (TSAP) sites were 
equivalent to, or indeed greater than, incidences reported in 
parts of Asia in the early 2000s1,2. In the previous studies, it 
is shown that the incidence of typhoid fever in Ghana was 
substantially different between adjacent urban and rural 
areas3. In another study conducted on TSAP found that the 
substantial prevalence of drug resistance and multidrug-
resistant strains of invasive Salmonella species circulating in 
sub-Saharan Africa4. There is a high prevalence of resistance 
to ﬁrst-line antimicrobial agents was identiﬁed in both S. 
typhi and nontyphoidal Salmonella isolates in some 
locations. These data are largely reﬂective of other 
observations in further sites in Africa and Asia5-8. 
Typhoid is the 5th most common communicable disease in 
India.  It is a major cause of absenteeism in schools and 
workplaces. Children constitute about 69% of hospitalized 
typhoid victims in India. Even sophisticated drugs are 
proving to be ineffective against resistant strains of typhoid 
bacteria. A retrospective hospital-based study at Safdarjang 
hospital-India was undertaken between January 1999 and 
December 2003 to estimate age-related epidemiological, 
clinical and microbiological characteristics in enteric fever 
cases, which showed that more than 24% of cases were in 
children up to 5 years of age 9.  In India, the disease is 
endemic in almost all parts of the country with periodic 
outbreaks of waterborne or foodborne diseases.  In 1992, 
about 3,52, 980 cases with 735 deaths were reported.  The 
number was 3,57, 452 cases and 888 deaths in 1993, 
whereas, in 1994, it declined to 2,78,451 cases and 304 
deaths10. In hospital-based studies and outbreak reports 
from India indicate that enteric fever is a major public health 
problem in this country, with S. typhi the most common 
etiologic agent but with an apparently increasing number of 
cases due to  S. paratyphi A11.   
The excessive antibiotic use causes an increased risk of 
infection with both drug-resistant and drug-sensitive 
serotypes of S. typhi12. The emergence of antimicrobial 
resistance in Salmonella strains is a serious health problem 
worldwide13. In the early 1960s, the first incidence of 
Salmonella resistance to a single antibiotic, namely 
chloramphenicol, was reported14. Since then, the frequency 
of isolation of Salmonella strains with resistance towards 
one or more antimicrobial agents has increased in many 
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countries, including the USA, the UK, and Saudi Arabia15. 
Antimicrobial agents such as ampicillin, chloramphenicol, 
and trimethoprim-sulfamethoxazole are used as the 
traditional first-line treatments for Salmonella infections. 
The Salmonella spp. are resistant towards these agents are 
referred to as multi-drug resistant (MDR). For many years, 
the phenotypic trait of MDR was widely distributed among S. 
typhi and at a lower rate, among S. paratyphi16.  
Africa and Asia are two continents with a high isolation 
frequency of S. typhi displaying MDR phenotype. In a 
surveillance study conducted in five Asian countries like 
India, Pakistan, Vietnam Indonesia, and China, among which 
the former three countries had higher rates of MDR isolates 
of S. typhi than Indonesia and China17. Other reports present 
similar data with a high rate of MDR isolates of S. typhi in 
Pakistan, India, Nepal, and Vietnam, while in China and 
Indonesia have less incidence rate of MDR S. typhi18. With 
the emergence of resistance towards traditional antibiotics, 
fluoroquinolones and extended-spectrum cephalosporins 
have been introduced as the antimicrobial agents of choice 
in treating MDR S. typhi19. nalidixic acid resistance, which is 
used as an indicator of reduced susceptibility of 
ciprofloxacin and other fluoroquinolones, is displayed by 
isolates from Pakistan, India, and Vietnam, with high 
incidence rates of 59%, 57% and 44%, respectively17. As for 
NTS, the number of strains developing MDR phenotype has 
increased in many countries since the first emergence of 
MDR S. typhimurium DT104 strains in 199020. NARMS 
presented data (from 1996–2007) which are more 
comprehensive, reporting the emergence of NTS isolates 
that are resistant to nalidixic acid and ceftriaxone. This 
phenomenon has raised concern among public health 
authorities regarding both clinical management and 
prevention of the infection21. A surveillance study on 
135,000 clinical isolates of NTS was conducted in Europe 
from 2000 to 2004, and the data showed that 15% of the 
isolates displayed MDR phenotype and 20% of the isolates 
were resistant to nalidixic acid22. 
The emergence of Salmonella with antimicrobial resistance 
is mainly promoted by the use of antibiotics in animal feed 
to promote the growth of food animals and in veterinary 
medicine to treat bacterial infections in those animals23. This 
poses a high risk of zoonotic disease with the transmission 
of MDR Salmonella strains from animals to humans via the 
ingestion of food or water contaminated with the animal 
feces with direct contact or the consumption of infected food 
of animals24. Moreover, MDR Salmonella strains were found 
in some exotic pet animals such as tortoises and turtles as 
well as their water environment and this could result in a 
higher risk of zoonotic infections in humans through direct 
contact with these animals25,26. The quinolones and third-
generation cephalosporins have been the antibiotics of 
choice in treating infections with MDR Salmonella27. 
Epidemiological studies show that MDR Salmonella strains 
cause more severe or prolonged syndromes than susceptible 
strains implying that the MDR strains are more virulent than 
the susceptible ones28. Data shows that patients infected 
with MDR Salmonella strains are more ill and septic at the 
onset of the disease and the illness is typically accompanied 
by high fever, enlargement of the spleen, liver and 
abdominal swelling29. 
MATERIALS AND METHODS 
Collection, processing of samples 
The samples from males, females, and children with the age 
group between 5 to 80 years were collected for 
epidemiological investigations from Kashmir. A total of 676 
samples were collected from various patients from hospitals 
and clinical laboratories. 
Antibiotic susceptibility testing by Kirby-Bauer disc 
diffusion method 
The cultures of S. typhi were prepared in broth medium. 
Inoculate the plate with the cultures by swabbing the entire 
surface of the plate. Then rotate the plate 45 and 90 degrees 
and using the same swab, streak the plate again. The lid was 
replaced and the swab was discarded. Then repeat the 
procedure for a new plate. Allow the plates to dry for 5 
minutes. Now use the sterile forceps and transfer different 
antibiotic discs to all the plate.  Then label the plates and 
incubate at 37°C for 24 hrs.  After incubation, the plates are 
examined and the diameter of zones of inhibition was 
measured. 
The Minimum inhibitory concentration (MIC) Method    
The minimum inhibitory concentration (MIC), which is the 
lowest concentration that still inhibits the growth of a 
particular organism can be determined using serial dilution 
methods. This procedure establishes the concentration of an 
antibiotic that is effective in preventing the growth of the 
pathogen and gives an indication of the dosage of that 
antibiotic that should be effective in controlling the infection 
in the patient.  
● Sterility checked peptone water was inoculated with 2-
5 morphologically similar colonies of Salmonella 
isolate. The broth was incubated at 37°C and turbidity 
matched to 0.5 Mac Farland standard. 
● The drug with different concentration was prepared in 
Mueller-Hinton media and was sterilized and cooled to 
50°C. Then the antibiotic suspension was added to 
each agar containing tube to get a fixed concentration 
of 0.25 μg/ml, 1 μg/ml and 2 μg/ml. These drugs 
containing agar tubes were poured into Petri dishes 
and allowed to solidify and then incubate at 37°C. 
● The grid was made on the drug-containing Mueller-
Hinton agar and spot inoculation of each isolate was 
made separately. The ATCC E. coli (25922) was used as 
a control plate.  
● The plates were incubated aerobically in an upright 
position at 37°C for 24 hours. 
● The drug-containing plate was examined for growth/no 
growth of the inoculated Salmonella isolates. The 
minimum concentration of different antibiotics 
inhibiting the growth of test strain (s) was recorded as 
the MIC of different antibiotics. 
RESULT AND DISCUSSION 
Antibiotic sensitivity  
The result of the in vitro antibiotic sensitivity test showed 
that isolates of S. typhi were generally resistant to antibiotics 
like chloramphenicol, ampicillin, tetracycline, cotrimoxazole, 
gentamycin, nalidixic acid (Table 1). The intermediate 
antibiotics were azithromycin and cefpodoxime whereas 
antibiotics such as ceftriaxone+salbactum, ciprofloxacin and 
ofloxacin were sensitive to S. typhi. In the present study, 
MDRP shows that ampicillin, co-trimoxazole, gentamycin, 
tetracycline, were resistant whereas ceftriaxone with 
sulbactam, ciprofloxacin and cefpodoxime were also 
sensitive against S. typhi (Table 1). 
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Table 1. Drug sensitivity pattern of S. typhi against various antibiotics. 
S. No Antibiotics Zone of inhibition 
(mm) 
Sensitivity (S), Intermediate (I), 
Resistant (R) 
1 Ampicillin 0 R 
2 Chloramphenicol 7.2 R 
3 Cotrimoxazole 0 R 
4 Gentamycin 0 R 
5 Tetracycline 0 R 
6 Azithromycin 10.0 I 
7 Ceftriaxone+ Salbactum 16.6 S 
8 Ciprofloxacin 14.8 S 
9 Cefpodoxime 10.2 I 
10 Nalidixic acid 0 R 
11 Ofloxacin 12.8 S 
S=Sensitivity, I=Intermediate, R=Resistant 
 
The fluoroquinolones (ofloxacin, ciprofloxacin) are widely 
regarded as optimal for the treatment of typhoid fever in 
adults30. They are relatively inexpensive, well tolerated and 
more rapidly and reliably effective than the former first-line 
drugs, viz. chloramphenicol, ampicillin, amoxicillin, and 
trimethoprim-sulfamethoxazole (Table 2). The majority of 
isolates are still sensitive. The fluoroquinolones attain 
excellent tissue penetration and kill S. typhi in its 
intracellular stationary stage in monocytes/macrophages 
and achieve higher active drug levels in the gall bladder than 
other drugs. They produce a rapid therapeutic response 
within three to five days and very low rates of post-
treatment carriage31,32.  
 
Table 2. Antibiotic susceptibility pattern of S. paratyphi A by disc diffusion method (N=178) 
S.  
No. 
Antibiotic Sensitive n (%) 
Intermediate n 
(%) 
Resistant n (%) 
1 Ampicillin 71.2(40) 1.78(1) 105.02(59) 
2 Amoxycillin & Clavulinic acid 150.41(84.5) 3.56(2) 24.03(13.5) 
3 Ceftriaxone & Salbactum 178(100) 0 0 
4 Chloramphenicol 165.896(93.2) 2.136(1.2) 9.968(5.6) 
5 Ciprofloxacin 178(100) 0 0(0) 
6 Co-trimoxazole 64.792(36.4) 0 113.208(63.6) 
7 Amikacin 178(100) 0 0 
8 Nalidixic acid 1.78(1) 0 176.22(99) 
 
There is no evidence of the superiority of any particular 
fluoroquinolone. The nalidixic acid and norfloxacin do not 
achieve adequate blood concentrations after oral 
administration and should not be used. No evidence of 
toxicity and impact on growth has been described in 
children with typhoid who have received ciprofloxacin33. For 
nalidixic-acid-sensitive S. typhi, seven-day regimens have 
proved highly effective. Courses of treatment of three and 
five days have also proved highly effective against nalidixic-
acid-sensitive strains. For nalidixic-acid-resistant infections, 
a minimum of seven days of treatment at the maximum 
permitted dosage is necessary and 10-14 days are usually 
required (Table 3). 
 
Table 3. Antibiotic susceptibility pattern of S. typhi by disc diffusion method (N=235) 
S.  
No. 
Antibiotic Sensitive n (%) 
Intermediate n 
(%) 
Resistant n (%) 
1 Ampicillin 123.37(52.5) 4.7(2) 106.92(55.5) 
2 Amoxycillin & Clavulinic acid 211.5(90) 2.35(1) 21.15(9) 
3 Ceftriaxone & Salbactum 235(100) 0 0 
4 Chloramphenicol 206.8(88) 7.05(3) 21.15(9) 
5 Ciprofloxacin 235(100) 0 0 
6 Co-trimoxazole 70.5(30) 4.7(2) 159.8(68) 
7 Amikacin 235(100) 0 0 
8 Nalidixic acid (0) 0 235(100) 
 
The recent emergence of resistance to fluoroquinolones, 
however, suggests that their widespread and indiscriminate 
use in primary care settings should be restricted. In areas of 
the world where the fluoroquinolones are not available or 
not registered for public health use and where the bacterium 
is still fully sensitive to traditional first-line drugs 
(chloramphenicol, amoxicillin or trimethoprim-
sulfamethoxazole), these remain appropriate for the 
treatment of typhoid fever. They are inexpensive, widely 
available and rarely associated with side-effects. 
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Antibiotic susceptibility pattern of S. typhi 
The sensitivity and resistant pattern of S. typhi for the period 
of Sep 2016 to June 2017, July 2016 to 1 April 2018 and May 
2018 to Feb 2019 are represented in Table 4, 5 and 6 
respectively. Antibiotic susceptibility pattern of S. typhi 
during the period Sep 2016 to June 2017 is given in table 4. 
Out of 676, the most sensitive antibiotics were ceftriaxone & 
sulbactam 90 (100%), ciprofloxacin 90 (100%) and 
ofloxacin 90 (100%) whereas the most resistant antibiotics 
were tetracycline 237 (87.77%) and amoxycillin 225 
(83.33%). Antibiotic susceptibility pattern of S. typhi during 
the period of July 2016 to 1 April 2018 is given in table 5.  
Out of 676, the most sensitive antibiotics were ceftriaxone & 
sulbactam was 100 (100%), cefuroxime 100 (100%) and 
ciprofloxacin 100 (100%) whereas the most resistant 
antibiotics were cotrimoxazole 184 (92.00%) and 
tetracycline 176 (88.00%). Antibiotic susceptibility pattern 
of S. typhi during the period of May 2018 to Feb 2019 is 
given in table 6. Out of 676, the most sensitive antibiotics 
were ceftriaxone & sulbactam was 95 (100%), cefuroxime 
92 (96.84%) and ciprofloxacin 93 (97.89%) whereas the 
most resistant antibiotics were amikacin 102 (49.51%) and 
cotrimoxazole 189 (91.74%). 
 
Table 4. Antibiotic susceptibility pattern of S. typhi during the period Sep 2016 to June 2017 
S. No. Antibiotics Sensitivity (%) n = 270 Resistant (%) N = 270 
1 Ampicillin 60 (22.22) 210 (77.77) 
2 Chloramphenicol 90 (33.33) 180 (66.66) 
3 Cotrimoxazole 39 (14.44) 221 (85.55) 
4 Tetracycline 33 (12.22) 237 (87.77) 
5 Ceftriaxone & Salbactum 270 (100) 00 (00) 
6 Cefuroxime 264 (97.77) 6 (2.22) 
7 Ciprofloxacin 270 (100) 00 (00) 
8 Ofloxacin 270(100) 00(00) 
9 Nalidixic acid 60 (22.22) 210 (77.77) 
10 Amikacin 261 (96.66) 9 (3.33) 
11 Gentamycin 42 (15.55) 218 (84.44) 
12 Amoxycillin 45 (16.66) 225 (83.33) 
 
Table 5. Antibiotic susceptibility pattern of S. typhi during the period 1st July 2017 to 1 April 2018 
S. No. Antibiotics Sensitivity (%) n = 200 Resistant (%) N = 200 
1 Ampicillin 44 (22.0) 156 (78.0) 
2 Chloramphenicol 62 (31.00) 138 (69.00) 
3 Cotrimoxazole 16 (8.00) 184 (92.00) 
4 Tetracycline 24 (12.00) 176 (88.00) 
5 Ceftriaxone & Salbactum 200(100) 00(00) 
6 Cefuroxime 200(100) 00 (00) 
7 Ciprofloxacin 200(100) 00 (00) 
8 Ofloxacin 188 (94.00) 12 (6.00) 
9 Nalidixic acid 30 (15.0) 170 (85.0) 
10 Amikacin 160 (80.00) 40 (20.00) 
11 Gentamycin 36 (18.00) 164 (82.00) 
12 Amoxycillin 44 (22.00) 156 (78.00) 
 
Table 6. Antibiotic susceptibility pattern of S. typhi during the period May 2018 to Feb 2019 
S. No. Antibiotics Sensitivity (%) n = 206 Resistant (%) N = 206 
1 Ampicillin 48 (23.30) 178 (76.69) 
2 Chloramphenicol 56 (27.18) 150 (72.81) 
3 cotrimoxazole 17 (8.25) 189 (91.74) 
4 Tetracycline 23 (11.16) 183 (88.83) 
5 Ceftriaxone &Salbactum 206 (100) 00 (00) 
6 Cefuroxime 199 (96.60) 7 (3.39) 
7 Ciprofloxacin 201 (97.57) 5 (2.48) 
8 Ofloxacin 190 (92.23) 16 (7.76) 
9 Nalidixic acid 26 (12.62) 180 (87.37) 
10 Amikacin 104 (50.48) 102 (49.51) 
11 Gentamycin 36 (17.47) 170 (82.52) 
12 Amoxycillin 35 (16.99) 171 (83.00) 
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Changing in sensitivity pattern of S. typhi  
The sensitivity of S. typhi isolates during the period of Sep 
2016 to June 2017, July 2016 to 1 April 2018 and May 2018 
to Feb 2019 are shown in Table 7. The change in sensitivity 
pattern during the period of Sep 2016 to June 2017, July 
2016 to 1 April 2018 and May 2018 to Feb 2019 of the drug 
Ceftriaxone and Salbactum, is 100%. The drug Cefuroxime is 
97.77%, 100 %, and 96.60%. The drug Ciprofloxacin 100%, 
100%, and 97.57%. The drug Ofloxacin is 100%, 94.00%, 
and 92.23%. The drug Amikacin 96.66%, 80.00%, and 
50.48%. 
 
Table 7. Changing in sensitivity pattern of S. typhi from Sep 2016 to June 2017, July 2016 to 1 April 2018 and May 2018 
to Feb 2019  
S. No. Antibiotics 
Sep 2016 to June 
2017 n= 90 % 
1st July 2017 to 1 April 
2018 n= 100% 
May 2018 to Feb 
2019 n=95 % 
1 Ampicillin 60 (22.22) 44 (22.0) 48 (23.30) 
2 Chloramphenicol 90 (33.33) 62 (31.00) 56 (27.18) 
3 Cotrimoxazole 39 (14.44) 16 (8.00) 17 (8.25) 
4 Tetracycline 33 (12.22) 24 (12.00) 23 (11.16) 
5 
Ceftriaxone & 
Salbactum 
270 (100) 200(100) 206 (100) 
6 Cefuroxime 264 (97.77) 200(100) 199 (96.60) 
7 Ciprofloxacin 270 (100) 200(100) 201 (97.57) 
8 Ofloxacin 270(100) 188 (94.00) 190 (92.23) 
9 Nalidixic acid 60 (22.22) 30 (15.0) 26 (12.62) 
10 Amikacin 261 (96.66) 160 (80.00) 104 (50.48) 
11 Gentamycin 42 (15.55) 36 (18.00) 36 (17.47) 
12 Amoxycillin 45 (16.66) 44 (22.00) 35 (16.99) 
 
Changing in the resistant pattern of S. typhi 
The resistant pattern of S. typhi isolates during the period of 
Sep 2016 to June 2017, July 2016 to 1 April 2018 and May 
2018 to Feb 2019 are shown in Table 8. The change in a 
resistant pattern during the period of Sep 2016 to June 2017, 
July 2016 to 1 April 2018 and May 2018 to Feb 2019 of the 
drug ampicillin is 77.77%, 78.0%, and 76.69%. The drug 
tetracycline is 87.77%, 88.00%, and 88.83%. The drug 
cotrimoxazole is 85.55%, 92.00%, and 91.74%. The drug 
amoxycillin is 83.33%, 78.00%, and 83.00%  
 
 
Table 8. Changing in the resistant pattern of S. typhi from Sep 2016 to June 2017, July 2016 to 1 April 2018 and May 
2018 to Feb 2019  
S. No. Antibiotics 
Sep 2016 to June 
2017, n= 90 % 
1st July 2017 to 1 April 
201 n= 100% 
May 2018 to Feb 2019, 
n=95 % 
1 Ampicillin 210 (77.77) 156 (78.0) 178 (76.69) 
2 Chloramphenicol 180 (66.66) 138 (69.00) 150 (72.81) 
3 Cotrimoxazole 221 (85.55) 184 (92.00) 189 (91.74) 
4 Tetracycline 237 (87.77) 176 (88.00) 183 (88.83) 
5 Ceftriaxone & Salbactum 00 (00) 00(00) 00 (00) 
6 Cefuroxime 6 (2.22) 00 (00) 7 (3.39) 
7 Ciprofloxacin 00 (00) 00 (00) 5 (2.48) 
8 Ofloxacin 00(00) 12 (6.00) 16 (7.76) 
9 Nalidixic acid 210 (77.77) 170 (85.0) 180 (87.37) 
10 Amikacin 9 (3.33) 40 (20.00) 102 (49.51) 
11 Gentamycin 218 (84.44) 164 (82.00) 170 (82.52) 
12 Amoxycillin 225 (83.33) 156 (78.00) 171 (83.00) 
 
Multidrug resistance (MDR) Strains 
The isolate showing drug resistance to more than three 
antibiotics is considered as multidrug resistant. The usual 
pattern of multidrug resistance of S. typhi shows the 
resistance of the combination of drugs like ampicillin, 
chloramphenicol and Tetracycline, and also a combination of 
drugs like ampicillin, chloramphenicol, and cotrimoxazole. 
The multidrug resistance of S. typhi during the period of 
three years, from Sep 2016 to Feb 2019 is shown in Table 9.   
Out of 676 isolates of S. typhi, the MDR for two drug 
combination cotrimoxazole and nalidixic acid is 35 (5.17%). 
In three-drug combination ampicillin, cotrimoxazole and 
nalidixic acid is 58 (8.57%). In four-drug combination 
ampicillin, cotrimoxazole, Nalidixic acid, and gentamycin is 
53 (7.84%). Five drug combination cotrimoxazole, 
tetracycline, nalidixic acid ampicillin, and amoxycillin is 115 
(17.01%). In six drug combination cotrimoxazole, 
tetracycline, nalidixic acid, ampicillin, chloramphenicol, and 
amoxycillin is 219 (32.39%). 
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Table 9.  Multidrug resistance of S. typhi for the period of Sep 2016 to June 2017, July 2016 to 1 April 2018 and May 
2018 to Feb 2019. 
S. No. MDR Pattern Antibiotics 
Resistant strains (%)   
n= 676 
1 Two drugs Cotrimaxazole and Nalidixic acid 35 (5.17) 
2 Three drugs Ampicillin, Cotrimaxazole and Nalidixic acid 58 (8.57) 
3 Four drugs Ampicillin, Cotrimaxazole, Nalidixic acid and Gentamycin 53 (7.84) 
2 Five drugs  Cotrimaxazole, Tetracycline, Nalidixic acid, Ampicillin 
and Amoxycillin 
115 (17.01) 
3 Six drugs  Cotrimaxazole, Tetracycline, Nalidixic acid, Ampicillin, 
Chloramphenicol and Amoxycillin 
219 (32.39) 
4 Seven drugs Ampicillin, Chloramphenicol, Cotrimaxazole, Tetracycline, 
Nalidixic acid, Amoxycillin and Amikacin 
113 (16.71) 
5 Eight drugs Ampicillin, Chloramphenicol, Cotrimaxazole, 
Ciprofloxacin, Ofloxacin, Nalidixic acid, Amikacin and 
Amoxycillin 
62 (9.17) 
6 Nine drugs Ampicillin, Chloramphenicol, Cotrimaxazole, Tetracycline, 
Ciprofloxacin, Ofloxacin, Amikacin, Gentamycin and 
Amoxycillin 
40 (5.91) 
 
Minimum Inhibitory Concentration (MIC) 
The MIC range MIC50 and MIC90 of all twelve drugs ampicillin, 
chloramphenicol, cotrimoxazole, tetracycline, ceftriaxone, 
cefuroxime, ciprofloxacin, ofloxacin, nalidixic acid, amikacin, 
gentamycin, and amoxycillin are represented in table 10. The 
MIC range of all 12 drugs used against the reprehensive 
strain of S.typhi. This result indicates the lowest and highest 
MIC values.  MIC50 and MIC 90 values were recorded in case of 
more than 50% and more than 90% of the total strains 
inhibited by the drugs at a particular concentration. For 
ampicillin MIC50 is 64.0 and MIC90 > 256.0. For 
chloramphenicol MIC50 is 16.0 and MIC90 > 256.0. For 
cotrimoxazole MIC50 is 32.0 and MIC90 128.0. 
 
Table 10. MIC range, MIC50 and MIC 90 of drugs against S. typhi 
S. 
No. 
Antibiotics MIC range MIC50 MIC90 
1 Ampicillin 16.0 to 256.0 64.0 > 256.0 
2 Chloramphenicol 8.0 to 256.0 16.0 > 256.0 
3 Cotrimaxazole 8.0 to 256.0 32.0 128.0 
4 Tetracycline 32.0 to 256.0 64.0 > 256.0 
5 Ceftriaxone 0.125 to 1.0 0.25 1.0 
6 Cefuroxime 0.125 to 1.0 4.0 8.0 
7 Ciprofloxacin 2.0 to 64.0 2.0 8.0 
8 Ofloxacin 2.0 to 256.0 8.0 128.0 
9 Nalidixic acid 64 to 156.0 64.0 256.0 
10 Amikacin 4.0 to 128.0 8.0 128.0 
11 Gentamycin 2.0 to 256 4.0 256.0 
12 Amoxycillin 8 to 64 8.0 256.0 
 
More than 90% of patients can be managed at home with 
oral antibiotics, reliable care and close medical follow-up for 
complications or failure to respond to therapy34. However, 
patients with persistent vomiting, severe , and abdominal 
distension may require hospitalization and parenteral 
antibiotic therapy. The efficacy availability and cost are 
important criteria for the selection of first-line antibiotics to 
be used in developing countries35,36. It should be noted that 
however, therapeutic strategies for children e.g. the choice of 
antibiotics, the dosage regimen and the duration of therapy 
may differ from those for adults. 
The S. typhi, particularly the multidrug-resistant (MDR) 
strain is relatively ubiquitous and is the cause of many 
community endemic and epidemic typhoid fever 
infections35,36. The MDR strain of S. typhi is of concern not 
only because of its resistance to available antibiotics 
resulting in high death rate but also because of its potential 
for epidemic outbreaks, which may be difficult to manage. 
The consequence of such an outbreak will no doubt be 
devastating especially in developing countries where health 
facilities are often inadequate.  
CONCLUSION 
The result of this study has further accentuated the growing 
concern about the presence and spread of multidrug-
resistant S. typhi thereby underscoring the need for the 
rational application of antibiotics and other necessary 
interventions that will help to control the menace of 
antibiotic resistance. They were, however, sensitive to 
ofloxacin even though these two antibiotics are no longer 
used for the treatment of typhoid fever on account of 
adverse reactions. The result of this study indicates that 
chloramphenicol and ofloxacin have proved to be active 
against these isolates even though they were resistant to the 
commonly prescribed drugs. This observation showed that 
an organism that is previously resistant to a particular 
antibiotic may become susceptible if treatment with the 
antibiotic is suspended for a long time. What has been 
reported earlier is interesting because of its obvious 
implication for public health management. However, more 
studies are recommended in this regard. 
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